TipRanks
Advertisement
Advertisement

APRE Stock Latest News

Aprea Therapeutics Expands Global IP for Precision Oncology
Company AnnouncementsAprea Therapeutics Expands Global IP for Precision Oncology
1M ago
8K
APRE
Aprea Therapeutics provides update on existing patent portfolio
PremiumThe Fly
Aprea Therapeutics provides update on existing patent portfolio
1M ago
APRE
Aprea Therapeutics reports Q2 EPS (7c), consensus (22c)
PremiumThe Fly
Aprea Therapeutics reports Q2 EPS (7c), consensus (22c)
2M ago
APRE
Aprea Therapeutics advances APR-1051 oncology pipeline progress
PremiumCompany Announcements
Aprea Therapeutics advances APR-1051 oncology pipeline progress
2M ago
8K
APRE
Aprea Therapeutics: Buy Rating Reiterated as APR-1051 Clinical Momentum Builds; $1.20 Price Target Maintained
PremiumRatings
Aprea Therapeutics: Buy Rating Reiterated as APR-1051 Clinical Momentum Builds; $1.20 Price Target Maintained
2M ago
APRE
Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors
PremiumCompany AnnouncementsAprea’s ATRN-119 Trial Completion: What It Means For APRE Investors
2M ago
APRE
Aprea Shareholders Approve Directors, Reverse Split Flexibility
Premium
Company Announcements
Aprea Shareholders Approve Directors, Reverse Split Flexibility
4M ago
8K
APRE
Pantginis Reiterates Buy on APR-1051 Developer, Keeps $1.20 Price Target After Encouraging ASCO Data and Superior Safety Profile
Premium
Ratings
Pantginis Reiterates Buy on APR-1051 Developer, Keeps $1.20 Price Target After Encouraging ASCO Data and Superior Safety Profile
4M ago
APRE
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target
PremiumRatings
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target
5M ago
APRE
Aprea Therapeutics price target lowered to $6 from $7 at Wedbush
PremiumThe Fly
Aprea Therapeutics price target lowered to $6 from $7 at Wedbush
5M ago
APRE
Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year
PremiumThe Fly
Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year
5M ago
APRE
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress
PremiumCompany Announcements
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress
5M ago
8K
APRE
Oracle upgraded, Planet Fitness downgraded: Wall Street’s top analyst calls
PremiumThe FlyOracle upgraded, Planet Fitness downgraded: Wall Street’s top analyst calls
5M ago
ABX
CNH
Aprea Therapeutics initiated with an Outperform at Oppenheimer
Premium
The Fly
Aprea Therapeutics initiated with an Outperform at Oppenheimer
5M ago
APRE
Aprea Therapeutics files to sell 74.35M shares of common stock for holders
Premium
The Fly
Aprea Therapeutics files to sell 74.35M shares of common stock for holders
5M ago
APRE
Aprea Therapeutics: Positive Read‑Through From Zentalis and Improving WEE1 Sentiment Support Buy Rating and $5 Target
PremiumRatings
Aprea Therapeutics: Positive Read‑Through From Zentalis and Improving WEE1 Sentiment Support Buy Rating and $5 Target
6M ago
APRE
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
PremiumCompany Announcements
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
6M ago
8K
APRE
Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
PremiumThe Fly
Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
6M ago
APRE
Aprea Therapeutics Announces $30 Million Private Placement
PremiumCompany Announcements
Aprea Therapeutics Announces $30 Million Private Placement
6M ago
8K
APRE
Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial
PremiumThe FlyAprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial
6M ago
APRE
Aprea Highlights Early APR-1051 Data and Financial Update
Premium
Company Announcements
Aprea Highlights Early APR-1051 Data and Financial Update
7M ago
8K
APRE
Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
Premium
The Fly
Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
7M ago
APRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >